Lung (Non-Small Cell) Cancer: E4512 (Hematology Oncology Associates)

ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.

The study drug, crizotinib, is already FDA-approved for use in ALK-positive locally advanced or metastatic (spread to other areas of the body) non-small lung cancer. The use of crizotinib in this study is investigational (not approved by the FDA) because crizotinib (or placebo) will be prescribed for earlier stage disease after the cancer has been surgically removed.

This study is related to the following study - A151216.

For more information, please visit the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Eastern Cooperative Oncology Group
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Health Care Cancer Clinic - Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office